Integrated Biopharma Inc (INBP) |
|
Price: $0.3100
$-0.01
-1.587%
|
Day's High:
| $0.3487
| Week Perf:
| -20.51 %
|
Day's Low: |
$ 0.30 |
30 Day Perf: |
-8.93 % |
Volume (M): |
17 |
52 Wk High: |
$ 0.42 |
Volume (M$): |
$ 5 |
52 Wk Avg: |
$0.28 |
Open: |
$0.34 |
52 Wk Low: |
$0.16 |
|
|
Market Capitalization (Millions $) |
10 |
Shares
Outstanding (Millions) |
31 |
Employees |
50 |
Revenues (TTM) (Millions $) |
50 |
Net Income (TTM) (Millions $) |
0 |
Cash Flow (TTM) (Millions $) |
0 |
Capital Exp. (TTM) (Millions $) |
1 |
Integrated Biopharma Inc
Integrated Biopharma Inc. is a publicly traded company based in the United States that operates in the biopharmaceutical industry. The company focuses on research, development, and production of specialty ingredients and raw materials for the health and nutritional industry. Integrated Biopharma specializes in the production of botanical extracts, dietary supplements, vitamins, and other natural health products. The company is committed to high quality and sustainable practices in its production processes. With a strong customer base, Integrated Biopharma Inc. aims to provide innovative and effective solutions to support the health and well-being of individuals worldwide.
Company Address: 225 Long Ave. Hillside 7205 NJ
Company Phone Number: 319-6962 Stock Exchange / Ticker: INBP
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Integrated Biopharma Inc
Integrated Biopharma Inc, a leading biopharmaceutical company, has recently released its financial results for the January to March 31, 2024 financial period. These results indicate several significant changes and improvements compared to the previous year. Firstly, the income per share for INBP remained unchanged at $0.01 per share, in contrast to the previous year where it was $0.00 per share. This shows stability and consistency in the company's earnings. Moreover, the income per share turned positive from a negative value of $-0.01 per share from the preceding reporting season. This demonstrates a positive shift in profitability for Integrated Biopharma Inc.
|
Integrated Biopharma Inc
Integrated Biopharma Inc is a pharmaceutical company that operates in the Major Pharmaceutical Preparations industry. In the most recent fiscal period, the company experienced a loss of $0.01 per share, compared to a profit of $0.03 per share the previous year and break-even results in the preceding financial reporting period. This decline in profitability is concerning for investors as it indicates a downward trend in the company's financial performance. One of the main reasons for the decline in profitability is the substantial decrease in revenue. Compared to the same period last year, revenue decreased by 14.15% to $10.52 million, and sequentially, revenue fell by 18.017% from $12.83 million. This drop in revenue is significant, especially when compared to the rest of the Major Pharmaceutical Preparations industry, which recorded a top-line improvement during the same period. This suggests that Integrated Biopharma Inc is not keeping up with its competitors, potentially due to various market factors or internal issues within the company.
|
Integrated Biopharma Inc
During the past week, Integrated Biopharma Inc (IBI) experienced a slight increase in its shares by 1.12%. This brings the year-to-date performance for IBI to a significant decrease of -23.27%. Currently, IBI shares are trading at a significant discount of -22.5% below its 52-week average. In terms of financial performance, IBI reported its most recent fiscal period with zero earnings per share (EPS), compared to the same period the previous year. This is also consistent with the preceding quarter. However, despite the lack of earnings, IBI's revenue saw a slight increase of 4.105% to $12.83 million, compared to $12.33 million in the same quarter a year ago. Sequentially, the company's revenue increased by 3.626% from $12.38 million.
|
Integrated Biopharma Inc
Integrated Biopharma Inc recently released its financial results for the fiscal period ending June 30, 2023. The report highlights a decrease in revenue, net earnings, as well as a decline in operating and net margins. Additionally, the company's stockpiles remain below the previous year's level. This article aims to outline the key facts from the financial results and provide an analysis of Integrated Biopharma Inc's performance. Financial Results Overview: 1. Earnings per Share (EPS): In the fiscal period ending June 30, 2023, Integrated Biopharma Inc recorded an EPS of $0.00 per share, compared to $0.05 per share in the same period a year ago. This figure also remained consistent with the preceding reporting period.
|
Integrated Biopharma Inc
Integrated Biopharma Inc's Fiscal Third Quarter of 2023: Insights and Analysis Integrated Biopharma Inc, a healthcare company operating in the United States, has recently released its financial results for the fiscal third quarter of 2023. In this article, we will delve into the details of the report and provide insights and analysis into the company's performance. The report shows that Integrated Biopharma Inc reached zero gain of $0.00 per share for the fiscal third quarter of 2023, in comparison to $0.03 per share in the same quarter a year earlier and in the preceding quarter. Correspondingly, revenue declined by -16.221% to $13.10 million from $15.63 million in the same quarter a year earlier, but increased sequentially by 6.888% from $12.25 million. Net profits of $0.016 million in the fiscal third quarter of 2023 dropped by -97.99% from zero gain in the corresponding period a year before.
|
Per Share |
Current |
Earnings (TTM) |
0.02 $ |
Revenues (TTM) |
1.65 $
|
Cash Flow (TTM) |
- |
Cash |
0.07 $
|
Book Value |
0.64 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
0.02 $
|
Revenues (TTM) |
1.65 $ |
Cash Flow (TTM) |
- |
Cash |
0.07 $
|
Book Value |
0.64 $ |
Dividend (TTM) |
0 $ |
|
|
|
Europe |
|
16.34 % |
of total Revenue |
Contract Manufacturing |
|
97.02 % |
of total Revenue |
Other Nutraceutical Business |
|
4.82 % |
of total Revenue |
UNITED STATES |
|
85.5 % |
of total Revenue |
UNITED STATES Contract Manufacturing |
|
80.68 % |
of total Revenue |
UNITED STATES Other Nutraceutical Business |
|
4.82 % |
of total Revenue |
Non-US |
|
16.34 % |
of total Revenue |
Non-US Contract Manufacturing |
|
16.34 % |
of total Revenue |
|
|